Note this deal was for a preclinical asset slated
Post# of 72440
(Total Views: 381)
Posted On: 05/11/2017 1:46:25 PM
Note this deal was for a preclinical asset slated to enter phase 1/2. 70M upfront, $300M in milestones. Does anyone believe we won't get a deal this good on an asset that has successfully completed phase 2b? SGMO has a $470M market cap and they are 5-10 years away from realizing royalties.
Assuming CTIX gets a similar deal and and market cap to this PRE-clinical compound/company we should rocket to $3.50+ which is 5x the current share price. That doesn't even begin to factor the lower risk to pharma or the fact that royalties could start coming in within two years on B or P.
The shorts can try as they might but they can't stop this train once the doors close.
Assuming CTIX gets a similar deal and and market cap to this PRE-clinical compound/company we should rocket to $3.50+ which is 5x the current share price. That doesn't even begin to factor the lower risk to pharma or the fact that royalties could start coming in within two years on B or P.
The shorts can try as they might but they can't stop this train once the doors close.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
Scroll down for more posts ▼